Drug Profile
Bersanlimab - BioInvent International
Alternative Names: BI-505Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator BioInvent International
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Intercellular adhesion molecule 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Multiple myeloma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Multiple-myeloma(Late-stage disease, Second-line therapy or greater) in Belgium (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Multiple-myeloma(Late-stage disease, Second-line therapy or greater) in Denmark (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Multiple-myeloma(Late-stage disease, Second-line therapy or greater) in Sweden (IV, Infusion)